Novo Nordisk A/S
A pharmaceutical company engaged in the research, development, manufacture and sale of treatments for chronic diseases. In addition to providing GLP-1 injections and human insulin preparations for the treatment of diabetes and obesity, the company also handles hemophilia treatments and growth hormone treatments. The company also develops new treatments and technologies, including stem cell-based cures, medical devices and digital health solutions.
Overview
Overview | |
|---|---|
Country | Denmark |
State | |
Employees | 64319 |
Founded | 1923 |
Financials | |
|---|---|
Market Capitalization | 637.08B |
Revenue | 35.35B |
Operating Income | 15.99B |
Operating Margin | 45.25% |
Net Income | 12.92B |
Ranking
Operating Income
Operating Income Ranking | |
|---|---|
All | 39 / 5373 |
Sector : Healthcare | 3 / 1144 |
Industry : Biotechnology | 1 / 645 |
Market Capitalization
Market Capitalization Ranking | |
|---|---|
All | 14 / 5565 |
Sector : Healthcare | 2 / 1182 |
Industry : Biotechnology | 1 / 670 |
Net Income
Net Income Ranking | |
|---|---|
All | 34 / 5436 |
Sector : Healthcare | 4 / 1164 |
Industry : Biotechnology | 1 / 659 |
Employees
Employees Ranking | |
|---|---|
All | 209 / 5330 |
Sector : Healthcare | 27 / 1174 |
Industry : Biotechnology | 1 / 667 |